DOV-216303
DOV 216,303 is a triple reuptake inhibitor that inhibits the reuptake of serotonin, norepinephrine, and dopamine with IC50 values of 14, 20, and 78 nM, respectively. It is an analogue of aminorex and DOV Pharmaceutical is the developer.
Pharmacology[edit | edit source]
DOV 216,303 is a potent inhibitor of the reuptake of serotonin, norepinephrine, and dopamine. This triple reuptake mechanism may provide a wider therapeutic range than traditional SSRIs or SNRIs. It is structurally related to aminorex, a stimulant drug that was withdrawn from the market due to severe side effects.
Development[edit | edit source]
DOV 216,303 was developed by DOV Pharmaceutical, a biopharmaceutical company that specializes in the development of novel therapeutics for neurological and psychiatric disorders. The drug was in Phase I clinical trials when DOV Pharmaceutical decided to discontinue its development.
See also[edit | edit source]
References[edit | edit source]
| DOV-216303 Resources | |
|---|---|
|
 |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
